TY - JOUR
T1 - The abundance of the long intergenic non-coding RNA 01087 differentiates between luminal and triple-negative breast cancers and predicts patient outcome
AU - De Palma, Fatima Domenica Elisa
AU - Del Monaco, Valentina
AU - Pol, Jonathan G.
AU - Kremer, Margerie
AU - D'Argenio, Valeria
AU - Stoll, Gautier
AU - Montanaro, Donatella
AU - Uszczyńska-Ratajczak, Barbara
AU - Klein, Cecilia C.
AU - Vlasova, Anna
AU - Botti, Gerardo
AU - D'Aiuto, Massimiliano
AU - Baldi, Alfonso
AU - Guigó, Roderic
AU - Kroemer, Guido
AU - Maiuri, Maria Chiara
AU - Salvatore, Francesco
N1 - Funding Information:
J.G.P. is supported by the S eerave Foundation, the Association Française d'Hépatologie (AFEF) and the S IRIC Cancer Research and Personalized Medicine (CARPEM). B.U.R. is supported by the National Science Center PL grant (2018/31/B/NZ2/01940). F.S. is supported by R egional/MIUR funds (Satin, Ciro, Campania Bioscience and Oncology 2020 (DGR n.7-15/01/2020) Projects) to fight against the oncological group of diseases. G.K. is supported by the Ligue contre le Cancer (équipe labellisée); Agence National de la Recherche (ANR)–Projets blancs; ANR under the frame of E-Rare-2, the ERA-Net for Research on Rare Diseases; Association pour la recherche sur le cancer (ARC); Cancéropôle Ile-de-France; Chancellerie des universités de Paris (Legs Poix), Fondation pour la Recherche Médicale (FRM); a donation by Elior; European Research Area Network on Cardiovascular Diseases (ERA-CVD, MINOTAUR); Gustave Roussy Odyssea, the European Union Horizon 2020 Project Oncobiome; Fondation Carrefour; High-end Foreign Expert Program in China (GDW20171100085), Institut National du Cancer (INCa); Inserm (HTE); Institut Universitaire de France; LeDucq Foundation; the LabEx Immuno-Oncology; the RHU Torino Lumière; the Seerave Foundation; the SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); and the SIRIC Cancer Research and Personalized Medicine (CARPEM).
Publisher Copyright:
© 2020 The Authors
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/11
Y1 - 2020/11
N2 - The molecular complexity of human breast cancer (BC) renders the clinical management of the disease challenging. Long non-coding RNAs (lncRNAs) are promising biomarkers for BC patient stratification, early detection, and disease monitoring. Here, we identified the involvement of the long intergenic non-coding RNA 01087 (LINC01087) in breast oncogenesis. LINC01087 appeared significantly downregulated in triple-negative BCs (TNBCs) and upregulated in the luminal BC subtypes in comparison to mammary samples from cancer-free women and matched normal cancer pairs. Interestingly, deregulation of LINC01087 allowed to accurately distinguish between luminal and TNBC specimens, independently of the clinicopathological parameters, and of the histological and TP53 or BRCA1/2 mutational status. Moreover, increased expression of LINC01087 predicted a better prognosis in luminal BCs, while TNBC tumors that harbored lower levels of LINC01087 were associated with reduced relapse-free survival. Furthermore, bioinformatics analyses were performed on TNBC and luminal BC samples and suggested that the putative tumor suppressor activity of LINC01087 may rely on interferences with pathways involved in cell survival, proliferation, adhesion, invasion, inflammation and drug sensitivity. Altogether, these data suggest that the assessment of LINC01087 deregulation could represent a novel, specific and promising biomarker not only for the diagnosis and prognosis of luminal BC subtypes and TNBCs, but also as a predictive biomarker of pharmacological interventions.
AB - The molecular complexity of human breast cancer (BC) renders the clinical management of the disease challenging. Long non-coding RNAs (lncRNAs) are promising biomarkers for BC patient stratification, early detection, and disease monitoring. Here, we identified the involvement of the long intergenic non-coding RNA 01087 (LINC01087) in breast oncogenesis. LINC01087 appeared significantly downregulated in triple-negative BCs (TNBCs) and upregulated in the luminal BC subtypes in comparison to mammary samples from cancer-free women and matched normal cancer pairs. Interestingly, deregulation of LINC01087 allowed to accurately distinguish between luminal and TNBC specimens, independently of the clinicopathological parameters, and of the histological and TP53 or BRCA1/2 mutational status. Moreover, increased expression of LINC01087 predicted a better prognosis in luminal BCs, while TNBC tumors that harbored lower levels of LINC01087 were associated with reduced relapse-free survival. Furthermore, bioinformatics analyses were performed on TNBC and luminal BC samples and suggested that the putative tumor suppressor activity of LINC01087 may rely on interferences with pathways involved in cell survival, proliferation, adhesion, invasion, inflammation and drug sensitivity. Altogether, these data suggest that the assessment of LINC01087 deregulation could represent a novel, specific and promising biomarker not only for the diagnosis and prognosis of luminal BC subtypes and TNBCs, but also as a predictive biomarker of pharmacological interventions.
KW - Biomarker
KW - Breast cancer
KW - LINC01087
KW - Long non-coding RNA
KW - Luminal breast cancer
KW - Triple-negative breast cancer
UR - http://www.scopus.com/inward/record.url?scp=85094836812&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85094836812&partnerID=8YFLogxK
U2 - 10.1016/j.phrs.2020.105249
DO - 10.1016/j.phrs.2020.105249
M3 - Article
C2 - 33068730
AN - SCOPUS:85094836812
VL - 161
JO - Pharmacological Research
JF - Pharmacological Research
SN - 1043-6618
M1 - 105249
ER -